Navigation Links
Pharmasset Reports Fiscal Year End 2011 Financial Results
Date:11/14/2011

PRINCETON, N.J., Nov. 14, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal year ended September 30, 2011. At fiscal year end Pharmasset held $166.5 million in cash and cash equivalents and used $21.7 million of our cash and cash equivalents during the fourth quarter of fiscal 2011.

Pipeline Update and 2011 HighlightsPSI-7977The recently-announced registrational program for PSI-7977, the once-a-day nucleotide analog for hepatitis C virus (HCV) infection, is the first to pursue an interferon-free, all-oral regimen, and the first to include patients with all HCV genotypes (GT). The three core studies will evaluate the all-oral two-drug combination of PSI-7977 and ribavirin (RBV) administered for 12 weeks.

The first trial, FISSION, is a pivotal study of PSI-7977 with RBV for 12 weeks in approximately 500 patients with HCV GT2 or GT3. FISSION is designed to demonstrate the superiority of PSI-7977/RBV over the current standard-of-care for HCV GT2/3, pegylated interferon (Peg-IFN) and ribavirin for 24 weeks. The second Phase 3 trial, POSITRON, is planned to begin in early 2012. POSITRON will enroll approximately 225 patients with HCV GT2 or GT3 who cannot take interferon, thus supporting a placebo comparator arm for this trial. During the first quarter of 2012, data from ongoing open-label assessments of PSI-7977/RBV in subjects with HCV GT1 in ELECTRON and QUANTUM will be reviewed and incorporated into the final design for the third registrational trial, NEUTRINO. This trial will also investigate a 12-week regimen of PSI-7977/RBV versus a placebo comparator, and will enroll approximately 280 patients with HCV regardless of viral genotype, inclu
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
5. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
10. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
11. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2013)... This training is ideal for those who will be ... industry or those who want to explore Agile and Scrum, ... topics that will be covered in the 1-day Agile and ... artifacts, and scrum simulation (optional). , The trainings will ... 28, 2013 , Click here to register for a class. ...
(Date:6/14/2013)... (PRWEB) June 14, 2013 Case ... LLC, SPR™ Therapeutics, and Valtronic, has been awarded ... Frontier Commission to commercialize a neurostimulation technology platform ... unmet needs, including pain and muscle paralysis. ... Program connects Ohio companies with the technology development ...
(Date:6/14/2013)... 14, 2013  Mast Therapeutics, Inc. (NYSE MKT: MSTX) ... of 50,000,000 units, each unit consisting of a fixed ... warrant to purchase 0.5 of a share of common ... unit.  The units will not be issued or certificated ... are immediately separable and will be issued separately, but ...
(Date:6/14/2013)... June 14, 2013 Smart Consulting Group ... provide consultation and staff augmentation services that helps the ... The Smart Consulting Group / Catalyst Group alliance is ... good manufacturing practices and superior quality standards ... FDA compliant manufacturing process is essential for all pharmaceutical ...
Breaking Biology Technology:Affordable Scrum Trainings in Denver, CO – 8 PDUs (June 28, 2013) by Conscires Agile Practices 2Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission 2Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission 3Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission 4Mast Therapeutics Prices Public Offering Of Units 2Mast Therapeutics Prices Public Offering Of Units 3Mast Therapeutics Prices Public Offering Of Units 4Smart Consulting Group and The Catalyst Group Form Alliance to Supply Quality Compliance Consulting Services For the Pharmaceutical Industry 2
... , , KNOXVILLE and OAK ... Ridge Innovation Valley ( www.knoxvilleoakridge.com ) see the successful test of ... , The Innovation Valley is home to Oak Ridge National Laboratory ... at the forefront of applied carbon fiber research. , ...
... NEW YORK, Dec. 18 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... a pharmaceutical,company dedicated to improving health through the development, ... over the counter ("OTC"),products, today announced that 158 of ... Insurance Catalog (the "2009 NIC"). Of these, 82,are categorized ...
... Department of Energy,s Pacific Northwest National Laboratory have ... the Advancement of Science for their exceptional efforts ... PNNL honorees and the AAAS sections that elected ... Yuehe Lin, chemistry; Philip Rasch, atmospheric and hydrospheric ...
Cached Biology Technology:Boeing Flight Boosts Carbon Fiber Hopes, Knoxville-Oak Ridge Innovation Valley Poised 2Boeing Flight Boosts Carbon Fiber Hopes, Knoxville-Oak Ridge Innovation Valley Poised 3American Oriental Bioengineering Announces the Inclusion of 158 Drugs in China's National Insurance Catalog 2American Oriental Bioengineering Announces the Inclusion of 158 Drugs in China's National Insurance Catalog 36 PNNL scientists elected AAAS fellows 26 PNNL scientists elected AAAS fellows 3
(Date:6/17/2013)... University research associate has received a prestigious fellowship to ... the spread of malaria. , Bart Bryant, research associate ... National Research Service Award Individual Postdoctoral Fellowship, which provides ... State University researcher to receive the award and is ... an award. , Bryant, a university doctoral graduate in ...
(Date:6/17/2013)... populations are declining worldwide and a major cause is ... but a two-year study shows they can also die ... a tolerant carrier host that just spreads the disease. ... controlled experimental conditions, they found at least one strain ... Bd or a chytrid fungus, can be fatal to ...
(Date:6/16/2013)... for female sex workers in India reduce rates of ... University of Toronto study has found. , ... in the southern states of Andhra Pradesh, Karnataka, Maharashtra ... Jha from U of T,s Dalla Lana School of ... Health Research (CGHR), examined the impact of prevention among ...
Breaking Biology News(10 mins):NIH fellowship helps researcher fight malaria, understand mosquito immunity 2Bullfrogs may help spread deadly amphibian fungus, but also die from it 2HIV prevention among female sex workers in India reduces HIV and syphilis 2
... polymers (LCP) as a viable tool for use in ... of Alberta researchers, collaborating with colleagues at the Eindhoven ... Netherlands, have shown that LCP, when formed into a ... and patterned on a microscale. The research was published ...
... cell fate decisions for many types of developing cells, according to ... sheds light on a puzzling behavior. For some differentiating stem ... to a new choice. In response to the initial ... different cell types. It often requires a second signal for ...
... with a single injection into a vein holds promise ... University of Florida researchers report. , UF researchers used ... a form of muscular dystrophy that damages the heart. ... and found genes were readily absorbed by heart muscle ...
Cached Biology News:Polymers show promise for lab-on-a-chip technology 2Researchers map out networks that determine cell fate 2Researchers map out networks that determine cell fate 3UF scientists test improved gene therapy method for hereditary heart conditions 2UF scientists test improved gene therapy method for hereditary heart conditions 3UF scientists test improved gene therapy method for hereditary heart conditions 4
... Columns, 10. *SizeSep 400 Spun Columns: For ... pairs in length. - ... in distilled water containing 0.15% Kathon CG/IcP Biocide. ... base pairs. *Extremely useful in the ...
... Light Diagnostics Universal Amplicon Detection ... use in the qualitative detection ... by in vitro nucleic ... only; not to be used ...
... Purification Kit, 25 purifications. Allows ... probesProvides efficient removal of unincorporated CyDye ... with superior yields of labeled cDNA ... of cDNA labeled by either direct ...
... Kit, 50 purifications. Allows rapid purification ... removal of unincorporated CyDye label and ... yields of labeled cDNA probe. ... labeled by either direct incorporation or ...
Biology Products: